Two Inodilators Postsurgery in Neonates

Status Completed

Clinical Trial Summary

Congenital heart defects are the most prevalent group of congenital malformations in newborns. Surgery-related low cardiac output syndrome (LCOS) could be one of the reason for the unfavourable outcome of this population. The early use of inodilators (INDs), specifically milrinone (MR), is proposed to reduce afterload and increase inotropism. Studies in the paediatric population appear to support a clinical usefulness of MR similar to that observed in adults. Levosimendan (LEVO) is a novel class IND developed for the treatment of heart failure. Experience with LEVO in paediatric patients is scarce. The purpose of this study was to systematically test the efficacy and safety of milrinone (MR) and levosimendan (LEVO) in newborns undergoing cardiovascular surgery with cardiopulmonary bypass (CPB). Given the uncertainty about LEVO pharmacokinetics in neonates, the study was designed as a pilot, phase I feasibility study.

Clinical Trial Description

Surgical repair is the primary therapy for congenital heart defects in the newborn. The neonatal cardiovascular system is at particular risk to develop the surgery-related low cardiac output syndrome (LCOS), thus vasoactive agents are routinely used in the postoperative management. Systematic research on the efficacy of these drugs is scarce in the newborn. As LCOS pathophysiology joints impaired myocardial contractility and the peripheral effects of ischemia/reperfusion injury on the endothelium, early use of inodilators (IND) are strongly recommended to reduce afterload and improve contractility. This study aims to test the equivalence in dose-dependent hemodynamic effects of 2 IND, Milrinone and Levosimendan, used early without loading dose in the preoperative period to prevent LCOS. By means of non-invasive technology the investigators will assess cardiac function (serial structural and functional echocardiography), the cerebral and peripheral perfusion and oxygenation (continuous near-infrared monitoring), cerebral function (continuous amplitude integrated EEG monitoring), will rule out CNS acquired lesions (serial transfontanelar echo-Doppler studies), and will follow up different biochemical markers of myocardial stress and apoptosis. Pharmacokinetic studies will be also performed. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01576094
Study type	Interventional
Source	Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	November 2009
Completion date	November 2010

View Details

See also
Status	Clinical Trial	Phase
Unknown status	`NCT00549107` - Prophylactic Use of Levosimendan Versus Milrinone in Open Heart Surgery in Infants	Phase 2
Completed	`NCT04045340` - Intraoperative Global Longitudinal Strain and Global Longitudinal Strain Rate as Predictors of Unfavorable Outcome in On-Pump Mitral Surgery
Completed	`NCT00619281` - How Much Cardiac Output is Enough?	N/A
Completed	`NCT00994825` - Levosimendan in High Risk Patients Undergoing Cardiac Surgery	Phase 4
Completed	`NCT03143348` - Prognostic Markers of Inflammation in Infants Undergoing Cardiopulmonary Bypass
Completed	`NCT02025621` - Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass	Phase 3
Completed	`NCT00695929` - Levosimendan in Congenital Cardiac Surgery	N/A
Completed	`NCT03661385` - Nitric Oxide During Bypass for Arterial Switch Operation	Phase 3
Completed	`NCT01120106` - Levosimendan Administration in Neonates With Transposition of the Great Arteries	Phase 2
Recruiting	`NCT03823781` - Prophylactic Use of Milrinone After Congenital Heart Surgery in Infants	Phase 3
Completed	`NCT01328912` - Remote Ischemic Preconditioning in High Risk Cardiovascular Surgery Patients	Phase 3
Recruiting	`NCT03558269` - Autologous Umbilical Cord Blood Treatment of Neonate With CHD	Phase 1/Phase 2
Recruiting	`NCT04405856` - Outcome of Patients Treated With IABP
Recruiting	`NCT04698005` - Exogenous Ketones for Acutely Decompensated HEart Failure	Phase 3
Active, not recruiting	`NCT05514652` - Anesthesia Standard Operating Procedure During On-pump Coronary Artery Bypass Grafting	N/A
Recruiting	`NCT06355882` - Patients With Low Cardiac Output Syndrome Undergoing Local Dental Anesthesia	N/A
Completed	`NCT03207165` - Milrinone Versus Dobutamine in Critically Ill Patients	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.